期刊文献+

经皮肝动脉热化疗灌注联合栓塞治疗原发性肝癌的应用研究 被引量:4

Research on transcatheter arterial thermo-chemotherapy and thermo-lipiodol embolization applied to hepatocellular carcinoma
暂未订购
导出
摘要 目的探讨经皮肝动脉热化疗灌注联合栓塞治疗原发性肝癌的应用价值。方法将68例原发性肝癌患者按随机数字表法随机分为对照组(32例)与观察组(36例)。给予观察组肝动脉置管,使用5-氟尿嘧啶、顺铂、丝裂霉素及表阿霉素行热灌注化疗栓塞。对照组在常温下进行导管灌注化疗栓塞。比较两组治疗后1年及2年生存率、近期治疗效果、肝功能改变以及不良反应发生率。结果观察组1年和2年生存率为75.0%和58.3%,显著高于对照组的56.3%和28.1%(P<0.05);观察组与对照组治疗总有效率分别为55.6%和31.3%,差异具有统计学意义(P<0.05);两组治疗后肝功能Child分级无统计学差异(P>0.05);治疗后观察组局部烧灼感发生率高于对照组(P<0.05),其余不良反应两组比较无统计学差异(P>0.05)。结论经皮肝动脉热化疗灌注联合栓塞可显著提高患者生存率,且安全有效。 Objective To explore the effect of transcatheter arterial thermo-chemotherapy and thermo-lipiodol embolization on hepa- tocellular carcinoma. Methods Sixty-eight patients with hepatocellular carcinoma were divided into control group ( n = 32) and trial group ( n = 36) at random. A catheter was set into the selected hepatic artery via femoral artery. The trial group was given ther- mo-chemotherapy [ 5-fluorouracil ( 5-Fu), cis-diamminedichloroplatinum ( cis-DDP), mitomycin and epirubicin ] and thermo-lipiodol embolization, and the control group received normal temperature chemotherapy and lipiodol embolization. Comparison was done on short-term therapeutic effect, liver function change, adverse reaction and 1-and 2-year survival rate between the two groups. Results The survival rate of 1-and 2-year was 75.0% and 58.3% in the trial group were, much higher than that (56.3% and 28.1% ) in the con- trol group (P 〈0.05). The effective rate was 55.6% in the trial group and 31.3% in the control group, between which there exis- ted a significant difference ( P 〈 0.05 ). There was no significant difference in Child classification of liver function between the two groups after treatment ( P 〉 0.05). The occurrence of feeling of cauterization was more common in the trial group than in the control group (P 〈 0.05 ), but the other adverse reactions were of no statistical difference (P 〉 0.05 ). Conclusion Transcatheter arterial thermo-chemotherapy plus thermo-lipiodol embolization can greatly improve clinical effect on hepatocellular carcinoma, and it' s safe.
出处 《临床军医杂志》 CAS 2013年第5期500-502,共3页 Clinical Journal of Medical Officers
基金 国家自然科学基金(81101485)
关键词 原发性肝癌 热化疗 栓塞 hepatocellular carcinoma thermo-chemotherapy embolization
  • 相关文献

参考文献8

二级参考文献61

共引文献94

同被引文献33

  • 1Martin J,Bhanot K,Athreya S. Complications and reinter- ventions in uterine artery embolization for symptomatic u- terine fibroids:a literature review and meta analysis [J]. Cardiovase Intervent Radiol, 2013,36 : 395-402.
  • 2European Association For The Study Of The Liver,Euro- pean Organisation For Research And Treatment Of Can- cer. EASLEORTC clinical practice guidelines:manage- ment of hepatocellular carcinoma [J]. J Hepatol,2012,56 (4) :908-943.
  • 3Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib inpatients in the Asia-Pacific region with ad- vanced hepatocellular carcinoma:a phase In randomised, double-blind,placebo-controlled trial [J]. Lancet Oncol, 2009,10(1) : 25-34.
  • 4Liang B,Zheng CS, Feng GS, et al. Correlation of hypoxi- ainducible factor lalpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal mod- el [J]. Cardiovase Intervent Radiol, 2010,33 (g) : 508-812.
  • 5Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma:an update [J]. Hepa- tol Res,2013,43(2) : 147-154.
  • 6Zhao Y, Wang W J, Guan S, et al. Sorafenib with transar- terial chemoembolization for the treatment of advanced hepatocellular carcinoma:a large-scale multicenter study of 222 patients [J]. Ann 0ncol,2013,24(7) : 1786-1792.
  • 7Du Y, Su T, Ding Y, et al. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation [J]. I-Iepat Mon, 2012 : e6031.
  • 8Zhou WP, Lai EC, Li AJ,et al. A prospective,random- ized, controlled trial of preoperative transartefial chemoe- mbolization for resectable large hepatocellular carcinoma Ann Surg,2009,249(2) : 195-202.
  • 9Kow AW,Kwon CH,Song S,et al.Risk factors of peri- toneal recurrence and outcome of resected peritoneal re- currence after liver resection in hepatocellular carcino- ma: review of 1222 cases of hepatectomy in a tertiary [J]. Ann Surge Oncol, 2012,19 ( 7 ) : 2246-2255.
  • 10Ho CM,Wu CY, Lee PH, et al. Analysis of the risk fac- tors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma [J]. Ann Surge 0ncol,2013,20(8) :2526-2533.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部